Danicopan manufacturers
- Danicopan
-
-
2026-07-30
- CAS:1903768-17-1
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kgs
- Danicopan
-
- $97.00
-
2026-07-27
- CAS:1903768-17-1
- Purity: 99.94%
- Supply Ability: 10g
- Danicopan
-
-
2025-11-19
- CAS:1903768-17-1
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1000kg
|
| | Danicopan Basic information |
| Product Name: | Danicopan | | Synonyms: | ACH-0144471;Danicopan;ACH-4471;Danicopan（ACH-4471）;2-Pyrrolidinecarboxamide, 1-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-2-pyridinyl)-4-fluoro-, (2S,4R)-;(2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide;ACH4471,Complement System,ACH 4471,Danicopan,inhibit,Inhibitor;Danicopan (ACH-4471) ，S0803 | | CAS: | 1903768-17-1 | | MF: | C26H23BrFN7O3 | | MW: | 580.41 | | EINECS: | | | Product Categories: | | | Mol File: | 1903768-17-1.mol |  |
| | Danicopan Chemical Properties |
| Boiling point | 841.7±65.0 °C(Predicted) | | density | 1.61±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:175.0(Max Conc. mg/mL);301.51(Max Conc. mM) | | form | A solid | | pka | 11.48±0.40(Predicted) | | color | White to off-white | | InChIKey | PIBARDGJJAGJAJ-NQIIRXRSSA-N | | SMILES | N1(C(CN2C3=C(C=C(C4=CN=C(C)N=C4)C=C3)C(C(C)=O)=N2)=O)C[C@H](F)C[C@H]1C(NC1=NC(Br)=CC=C1)=O |
| | Danicopan Usage And Synthesis |
| Uses | Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)[1]. | | References | [1] Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar;102(3):466-475. DOI:10.3324/haematol.2016.153312
[2] Boyer DD, Ko YP, Podos SD, et al. Danicopan, an Oral Complement Factor D Inhibitor, Exhibits High and Sustained Exposure in Ocular Tissues in Preclinical Studies. Transl Vis Sci Technol. 2022;11(10):37. DOI:10.1167/tvst.11.10.37 |
| | Danicopan Preparation Products And Raw materials |
|